Posts Tagged ‘ avastin ’
Avastin/Lucentis Update 47: Should the UK’s NICE Consider Adding Avastin to It’s Approved Drugs?
In a blog, appearing on the BMJ (British Medical Journal) Group Blogs, James Raftery, a health economist with several decades' experience with the National Health Service (NHS) and a professor of health technology assessment at Southampton University, regularly writes about NICE (the UK’s National Institute for Health and Clinical Excellence). He is a keen "NICE-watcher," and has provided economic input to technical assessment reports for NICE.
In this blog entry, he discusses the case to be made for including Avastin in the approved drug registry for treating AMD and DMO (or DME, as we know it).
Avastin Just as Good as Lucentis
It's official. Avastin is just as good as Lucentis for the treatment of wet macular degeneration.
The results of this National Eye Institute study were released just a week ago. The study, Comparison of Age-Related Macular Degeneration Treatment Trials (CATT) compared the two drugs head-to-head in a year long study involving about 1200 patients.
Better still, the study showed that dosing “as needed” may be just as good a therapy a (Read more...)
CATT Update 15: Preliminary Two-Year Safety Data Presented at ARVO
Two of the authors of the CATT Study, that was published in the NEJM last Thursday, Drs. Dan Martin and Maureen McGovern, presented additional information about the study at the opening day ARVO Meeting, to about 2000 eager attendees. As reported by MedPageToday, their presentation included preliminary two-year safety data from the landmark CATT trial.
CATT Study Update 12: Status of WorldWide Studies
With the anticipated arrival of the one-year results of the CATT Study this Spring, I thought it would be appropriate to update where the other worldwide studies stand.
Avastin/Lucentis Update 43: Secret Rebates Offered for Lucentis
First, Genentech refused to provide Lucentis for the CATT Study [...]; then they threatened to stop supplying Avastin to compounding pharmacies [...]; then they decided to provide Lucentis free of charge for the study looking at the use of panretinal laser treatment plus anti-VEGF (Lucentis) in the treatment of diabetic macular edema [...]; and now, the company is offering secret rebates to selected large users of Lucentis – obviously to blunt the potential expected to be offered by Avastin when the CATT Study results are released next Spring.
Drugs for macular degeneration
(Boston) Scientists from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the therapy of age-related macular degeneration (AMD). The study, which appears currently on-line in Eye, is thought to bethe first study to describe one-year outcomes of a prospective, double-masked, randomized clinical trial directly comparing bevacizumab to ranibizuamab. Last October, these same scientists published early, six month outcomes of the same study, which also failed to show a difference in efficacy between these two drugs for treating AMD........
Subscribe
